In 2014 India's bio-economy was worth about $10 billion — a modest slice of a country better known for IT and generic pharma. Over the next decade it expanded more than thirteen-fold, past $130 billion by 2024, spanning bio-pharma, bio-agriculture, bio-industrial and bio-energy. In August 2024 the Cabinet approved the BioE3 policy to push the next leap.
Bio-economy · BioE3
Bio-economy · BioE3
India's bio-economy — biotech medicines, vaccines, bio-agriculture, bio-industrial products — grew roughly thirteen-fold, from about $10 billion in 2014 to over $130 billion by 2024. The BioE3 policy, approved in August 2024, aims to make India a global bio-manufacturing hub. The counter shows that growth.
$130 bn+
Bio-economy size (2024)
13x
Growth since 2014
$300 bn
Target by 2030
Bio-economy (2014→2024)
| Year | Bio-economy size |
|---|---|
| 2014 | 10 $ bn |
| 2016 | 26 $ bn |
| 2018 | 48 $ bn |
| 2020 | 70 $ bn |
| 2022 | 100 $ bn |
| 2024 | 130 $ bn |
| 2026 | 165 $ bn |
2014
0$ bn
Bio-economy size
20142026
Since 2014
Added
+155 $ bn
2014
10 $ bn
2026
165 $ bn
Why it matters Biology is becoming a manufacturing platform — engineered cells can make fuels, plastics, medicines and food more sustainably than fossil chemistry. BioE3 (Biotechnology for Economy, Environment and Employment) bets that India, already the 'pharmacy of the world', can lead this bio-revolution and reach a $300 billion bio-economy by 2030.
- India's bio-economy grew from ~$10 billion (2014) to over $130 billion (2024).
- The BioE3 policy was approved by the Union Cabinet on 24 August 2024.
- It funds Biomanufacturing, Bio-AI hubs and biofoundries for high-performance bio-manufacturing.
- India targets a $300 billion bio-economy by 2030 and produces ~60% of the world's vaccines.
History
Notable milestone
The BioE3 policy — Biotechnology for Economy, Environment and Employment — was approved on 24 August 2024. It moves India from doing biology in labs to manufacturing with biology at scale, via dedicated Biomanufacturing hubs, Bio-AI hubs and biofoundries. The number of bio-economy firms nearly doubled from ~5,400 (2021) to ~10,000 (2024).
How it works
A biofoundry is like a factory for biology — engineered microbes and cells are designed, tested and scaled to produce fuels, chemicals, materials, medicines and foods. BioE3 backs R&D, start-ups and shared infrastructure across priority themes, so founders get 'plug-and-play' lab space instead of building it from scratch.
Outlook
The prize is both economic and green: bio-manufacturing can cut dependence on fossil-based chemistry, support 'net-zero' and circular-economy goals, and create high-skill jobs. India already makes about 60% of the world's vaccines, giving it a manufacturing base few countries can match.
The road ahead
Scaling biology is capital-intensive and slow — hubs cost thousands of crores to build and run, and today the bio-economy is concentrated in a few western and southern states, with the east and northeast under 6%. Sustained funding, talent and spreading the base geographically will decide whether the $300 billion by 2030 target is met.
By the numbers
$10 bn (2014) → $130 bn+ (2024) bio-economy — over 13x. $300 bn target by 2030. ~10,000 bio-economy firms (2024), up from ~5,400 (2021). ~60% of the world's vaccines made in India. BioE3 approved 24 Aug 2024. Sources: Dept of Biotechnology, PIB.
Source: Dept of Biotechnology — India's bio-economy size; BioE3 policy (2024). Endpoints official, curve illustrative.